Krystal Biotech stock: KB113 data show broad tumor regression
Published on 10/30/2026 at 03:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKB113 data and development path
- Zacks described early KB113 findings as showing broad regression across assessed basal-cell-carcinoma lesions.
- Krystal Biotech has begun discussions with the FDA about the program's advanced clinical development.
Krystal Biotech's investigational KB113 showed broad tumor regression in an early Gorlin syndrome study, according to a Zacks Equity Research report published on October 16, 2026. The report said the intratumoral immunotherapy is being developed for basal cell carcinomas in patients with Gorlin syndrome.
Early signal from a small study
Zacks reported that three adult patients received six KB113 doses over 14 weeks. At the final assessment, 69 of 83 assessed landmark lesions showed some clinical regression. Responses were also observed in lesions that were not directly injected, a finding the report said was consistent with a possible systemic immune-mediated effect.
The report also described three injected lesions with histologically confirmed complete responses after at least 90% clinical regression. Treatment was well tolerated in all three patients. These findings are preliminary, and the small study population means that further clinical development will be needed to assess the candidate's safety and efficacy more broadly.
FDA discussions add a development milestone
Krystal Biotech has initiated discussions with the U.S. Food and Drug Administration about the advanced clinical development of KB113 for Gorlin syndrome. The company plans to provide an update on its development plans after aligning with the FDA. That process is a development milestone, but it does not yet establish regulatory approval or commercial availability for KB113.
For investors, KB113 gives Krystal Biotech an additional pipeline program alongside its marketed gene therapy business. The early data provide a clinical signal, while the limited sample size and the need for further development remain important considerations when assessing the program's potential.
Current quote and investor context
Lang & Schwarz quoted the stock at 290.00 euros on October 29, 2026, at 23:00 Berlin time. The quote was above the previous close of 289.90 euros in the licensed market data. The real-time quote of Krystal Biotech stock provides the latest available market reading.
Krystal Biotech stock at a glance
- Company: Krystal Biotech, Inc.
- ISIN: US5011471027
- Ticker: KRYS
- Lang & Schwarz quote: 290.00 euros on October 29, 2026, at 23:00 Berlin time
- Previous close in the same quote: 289.90 euros
- Pipeline program: KB113 for basal cell carcinomas associated with Gorlin syndrome
Broader U.S. equity-market developments can be followed through the S&P 500 market overview.
More developments are available in more news and analyses on Krystal Biotech stock.
